SEARCH:   Advanced

Blood, 15 July 2005, Vol. 106, No. 2, pp. 713-716. Prepublished online as a Blood First Edition Paper on April 7, 2005; DOI 10.1182/blood-2005-01-0373. This Article Full Text (PDF) All Versions of this Article: 2005-01-0373v1 106/2/713    most recent Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Rights and Permissions Citing Articles Citing Articles via HighWire Citing Articles via CrossRef Citing Articles via Google Scholar Google Scholar Articles by Tassone, P. Articles by Munshi, N. C Search for Related Content PubMed PubMed Citation Articles by Tassone, P. Articles by Munshi, N. C Related Collections Related Article in Blood Online Social Bookmarking                   What's this?  Previous Article  |  Next Article  Submitted February 9, 2005 Accepted March 3, 2005 A clinically relevant SCID-hu in vivo model of human multiple myeloma Pierfrancesco Tassone, Paola Neri, Daniel R Carrasco, Renate Burger, Victor S Goldmacher, Robert Fram, Vidit Munshi, Laurence Catley, Gary S Jacob, Salvatore Venuta, Kenneth C Anderson, and Nikhil C Munshi* Jerome Lipper Multiple Myeloma Center, Dana-Farber Cancer Institute, Boston, MA, USA; VA Boston Healthcare System, Harvard Medical School, Boston, MA, USA; University of 'Magna Graecia', Catanzaro, Italy Jerome Lipper Multiple Myeloma Center, Dana-Farber Cancer Institute, Boston, MA, USA ImmunoGen, Inc., Cambridge, MA, USA VA Boston Healthcare System, Harvard Medical School, Boston, MA, USA Callisto Pharmaceuticals Inc., New York, NY, USA University of 'Magna Graecia', Catanzaro, Italy Jerome Lipper Multiple Myeloma Center, Dana-Farber Cancer Institute, Boston, MA, USA; VA Boston Healthcare System, Harvard Medical School, Boston, MA, USA * Corresponding author; email: Nikhil_Munshi{at}dfci.harvard.edu. We developed a novel in vivo multiple myeloma (MM) model by engrafting the IL-6-dependent human MM cell line INA-6 into SCID mice previously transplanted with a human fetal bone chip (SCID-hu mice). INA-6 cells require either exogenous human IL-6 (huIL-6) or bone marrow stromal cells (BMSCs) to proliferate in vitro. In this model, we monitored the in vivo growth of INA-6 cells stably transduced with a green fluorescent protein gene (INA-6GFP+ cells). INA-6 MM cells engrafted in SCID-hu mice, but not in SCID mice that had not been implanted with human fetal bone. The level of soluble human IL-6 receptor (shuIL-6R) in serum and fluorescence imaging of host animals were sensitive indicators of tumor growth. Dexamethasone as well as experimental drugs, such as Atiprimod and B-B4-DM1, were used to confirm the utility of the model for evaluation of anti-MM agents. We report that this model is highly reproducible and allows for evaluation of investigational drugs targeting IL-6 dependent MM cells in the human bone marrow (huBM) milieu. CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    What's this? Related Article in Blood Online: A clinically relevant mouse model of human multiple myeloma? Soldano Ferrone and Giuseppe Sconocchia Blood 2005 106: 388-389. [Full Text] [PDF] This article has been cited by other articles: M. Fulciniti, T. Hideshima, C. Vermot-Desroches, S. Pozzi, P. Nanjappa, Z. Shen, N. Patel, E. S. Smith, W. Wang, R. Prabhala, et al. A High-Affinity Fully Human Anti-IL-6 mAb, 1339, for the Treatment of Multiple Myeloma Clin. Cancer Res., December 1, 2009; 15(23): 7144 - 7152. [Abstract] [Full Text] [PDF] M. Fulciniti, P. Tassone, T. Hideshima, S. Vallet, P. Nanjappa, S. A. Ettenberg, Z. Shen, N. Patel, Y.-t. Tai, D. Chauhan, et al. Anti-DKK1 mAb (BHQ880) as a potential therapeutic agent for multiple myeloma Blood, July 9, 2009; 114(2): 371 - 379. [Abstract] [Full Text] [PDF] P. L. Bergsagel and W. M. Kuehl WSU-WM and BCWM.1 should not be assumed to represent Waldenstrom macroglobulinemia cell lines Blood, August 1, 2008; 112(3): 917 - 917. [Full Text] [PDF] H. Rozemuller, E. van der Spek, L. H. Bogers-Boer, M. C. Zwart, V. Verweij, M. Emmelot, R. W. Groen, R. Spaapen, A. C. Bloem, H. M. Lokhorst, et al. A bioluminescence imaging based in vivo model for preclinical testing of novel cellular immunotherapy strategies to improve the graft-versus-myeloma effect Haematologica, July 1, 2008; 93(7): 1049 - 1057. [Abstract] [Full Text] [PDF] S. Vallet, N. Raje, K. Ishitsuka, T. Hideshima, K. Podar, S. Chhetri, S. Pozzi, I. Breitkreutz, T. Kiziltepe, H. Yasui, et al. MLN3897, a novel CCR1 inhibitor, impairs osteoclastogenesis and inhibits the interaction of multiple myeloma cells and osteoclasts Blood, November 15, 2007; 110(10): 3744 - 3752. [Abstract] [Full Text] [PDF] P. Neri, S. Kumar, M. T. Fulciniti, S. Vallet, S. Chhetri, S. Mukherjee, Y. Tai, D. Chauhan, P. Tassone, S. Venuta, et al. Neutralizing B-Cell Activating Factor Antibody Improves Survival and Inhibits Osteoclastogenesis in a Severe Combined Immunodeficient Human Multiple Myeloma Model Clin. Cancer Res., October 1, 2007; 13(19): 5903 - 5909. [Abstract] [Full Text] [PDF] M. Wang, L. Zhang, X. Han, J. Yang, J. Qian, S. Hong, F. Samaniego, J. Romaguera, and Q. Yi Atiprimod inhibits the growth of mantle cell lymphoma in vitro and in vivo and induces apoptosis via activating the mitochondrial pathways Blood, June 15, 2007; 109(12): 5455 - 5462. [Abstract] [Full Text] [PDF] A.-S. Moreau, X. Jia, H. T. Ngo, X. Leleu, G. O'Sullivan, Y. Alsayed, A. Leontovich, K. Podar, J. Kutok, J. Daley, et al. Protein kinase C inhibitor enzastaurin induces in vitro and in vivo antitumor activity in Waldenstrom macroglobulinemia Blood, June 1, 2007; 109(11): 4964 - 4972. [Abstract] [Full Text] [PDF] S. R. Choudhari, M. A. Khan, G. Harris, D. Picker, G. S. Jacob, T. Block, and K. Shailubhai Deactivation of Akt and STAT3 signaling promotes apoptosis, inhibits proliferation, and enhances the sensitivity of hepatocellular carcinoma cells to an anticancer agent, Atiprimod Mol. Cancer Ther., January 1, 2007; 6(1): 112 - 121. [Abstract] [Full Text] [PDF] W. Dalton and K. C. Anderson Synopsis of a Roundtable on Validating Novel Therapeutics for Multiple Myeloma. Clin. Cancer Res., November 15, 2006; 12(22): 6603 - 6610. [Abstract] [Full Text] [PDF] T. Hideshima, P. Neri, P. Tassone, H. Yasui, K. Ishitsuka, N. Raje, D. Chauhan, K. Podar, C. Mitsiades, L. Dang, et al. MLN120B, a Novel I{kappa}B Kinase {beta} Inhibitor, Blocks Multiple Myeloma Cell Growth In vitro and In vivo. Clin. Cancer Res., October 1, 2006; 12(19): 5887 - 5894. [Abstract] [Full Text] [PDF] T. Hideshima, L. Catley, H. Yasui, K. Ishitsuka, N. Raje, C. Mitsiades, K. Podar, N. C. Munshi, D. Chauhan, P. G. Richardson, et al. Perifosine, an oral bioactive novel alkylphospholipid, inhibits Akt and induces in vitro and in vivo cytotoxicity in human multiple myeloma cells Blood, May 15, 2006; 107(10): 4053 - 4062. [Abstract] [Full Text] [PDF] T. Hideshima, D. Chauhan, P. Richardson, and K. C. Anderson Identification and Validation of Novel Therapeutic Targets for Multiple Myeloma J. Clin. Oncol., September 10, 2005; 23(26): 6345 - 6350. [Abstract] [Full Text] [PDF]

	Copyright © 2005 by American Society of Hematology         Online ISSN: 1528-0020